Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS | P14324 | 4/20 | 0.36 |
| ▸ | HTR7 | P34969 | 4/20 | 0.35 |
| ▸ | MAPK14 | Q16539 | 8/20 | 0.34 |
| ▸ | TYK2 | P29597 | 1/20 | 0.34 |
| ▸ | CAMK2D | Q13557 | 1/20 | 0.32 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.32 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.32 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20197172 | 0.85 | MAPK14 (0.42) | FDPSHTR7MAPK14MAPK10HRH4 | |
| SCHEMBL3555705 | 0.76 | HTR7 (0.59) | HTR7MAPK14CAMK2D | |
| SCHEMBL2730632 | 0.74 | — | — | |
| SCHEMBL1587747 | 0.73 | HRH4 (0.52) | MAPK14HRH4 | |
| SCHEMBL23212152 | 0.71 | TYK2 (0.57) | TYK2 | |
| SCHEMBL18298481 | 0.71 | MAPK14 (0.47) | MAPK14 | |
| SCHEMBL18298479 | 0.71 | MAPK14 (0.47) | MAPK14 | |
| SCHEMBL20260379 | 0.71 | JAK2 (0.47) | HTR7MAPK14 | |
| SCHEMBL31734260 | 0.70 | — | — | |
| SCHEMBL13457807 | 0.69 | NOS2 (0.39) | HTR7MAPK14HRH4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180086733-A1 | PYRIDINYL QUINOLINONE DERIVATIVES AS MUTANT-ISOCITRATE DEHYDROGENASE INHIBITORS | FORMA THERAPEUTICS, INC. | 2018-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180086733-A1 | PYRIDINYL QUINOLINONE DERIVATIVES AS MUTANT-ISOCITRATE DEHYDROGENASE INHIBITORS | IDH1, IDH3A, IDH3B | FDPS 855/4885HTR7 4285/4885MAPK14 3446/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.